Overweight in mice, induced by perinatal programming, exacerbates doxorubicin and trastuzumab cardiotoxicity.
Fiche publication
Date publication
avril 2016
Journal
Cancer chemotherapy and pharmacology
Auteurs
Membres identifiés du Cancéropôle Est :
Pr COTTIN Yves, Pr VERGELY Catherine
Tous les auteurs :
Guenancia C, Hachet O, Aboutabl M, Li N, Rigal E, Cottin Y, Rochette L, Vergely C
Lien Pubmed
Résumé
Trastuzumab (TRZ) is believed to potentiate doxorubicin (DOX) cardiotoxicity, resulting in left ventricular dysfunction. There is some evidence that overweight could influence anticancer drug-induced cardiotoxicity, though no study has evaluated the impact of moderate overweight, induced by postnatal nutritional programming, on the cardiotoxic effects of DOX alone or in combination with TRZ.
Mots clés
Animals, Antineoplastic Agents, toxicity, Cardiotoxicity, Doxorubicin, toxicity, Female, Heart, drug effects, Mice, Mice, Inbred C57BL, Overweight, complications, Trastuzumab, toxicity, Ventricular Function, Left, drug effects
Référence
Cancer Chemother. Pharmacol.. 2016 Apr;77(4):777-85